CALGARY, AB,
March 24, 2022 /CNW/ -
Universal Ibogaine (TSXV: IBO) (OTCQB: IBOGF), a life sciences
company with a mission to transform the world of addiction
treatment through medicalized ibogaine and a state of the art
ongoing care program, announced today that Company CEO
Nick Karos has been invited to
present at the 2022 Virtual Growth Conference, presented by Maxim
Group LLC and hosted by M-Vest, on March
28th - 30th from 9:00 a.m. - 5:00
p.m. EDT.
Sign up here to access the presentation
During this virtual conference, investors will hear from
executives from a wide range of sectors including Biotech, Clean
Energy, Electric Vehicles, Financial Services, Fintech & REITS,
Gaming & Entertainment, Healthcare, Healthcare IT,
Infrastructure, Shipping and Technology/ Media/Telecom. The
conference will feature company presentations, fireside chats,
roundtable discussions, and live Q&A with CEOs moderated by
Maxim Research Analysts.
This conference will be live on M-Vest. To attend, just sign up
to become an M-Vest member.
Click Here to Reserve your seat
About Universal Ibogaine Inc.
UI is a life sciences company, with a mission to demonstrate the
safety and efficacy of its ibogaine based drug detox protocol
through a planned Canadian Clinical Trial, and ultimately to
utilize that protocol globally through future licensing agreements.
UI is concurrently developing a state-of-the-art holistic addiction
treatment protocol at its Kelburn Recovery Centre in Winnipeg, Manitoba that, when paired with the
planned ibogaine detox protocol, is intended to revolutionize the
way we treat addiction and drastically improve the lives of
individuals and families affected by addiction.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES
PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX
VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS
This news release may contain forward-looking statements and
information. Forward-looking information is frequently
characterized by words such as "plans", "expect", "project",
"intend", "will", "believe", "anticipate", "estimate", "scheduled",
"potential", or other similar words, or statements that certain
events or conditions "may", "should" or "could" occur. The
forward-looking statements and information are based on certain key
expectations and assumptions made by UI. Although UI believes that
the expectations and assumptions on which the forward-looking
statements are based are reasonable, undue reliance should not be
placed on the forward-looking statements because UI can give no
assurance that they will prove to be correct.
Since forward-looking statements address future events and
conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those
currently anticipated due to a number of factors and risks, which
include, but are not limited to, risks that required regulatory
approvals are not obtained. The reader is cautioned that
assumptions used in the preparation of such information, although
considered reasonable by UI at the time of preparation, may prove
to be incorrect and readers are cautioned not to place undue
reliance on forward-looking information, which speaks only to
conditions as of the date hereof. UI does not undertake any
obligation to release publicly any revisions to forward-looking
information contained herein to reflect events or circumstances
that occur after the date hereof or to reflect the occurrence of
unanticipated events, except as may be required under applicable
securities laws.
Related Links
Universal Ibogaine
SOURCE Universal Ibogaine Inc.
